Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B

Cancer Medicine

Volumn 1, Issue 2, 2012, Pages 187-197

  Sharma, Pankaj ^a   Patel, Divya ^a   Chaudhary, Jaideep ^a  

^a CLARK ATLANTA UNIVERSITY   (United States)

Author keywords

Id1; Id2; Id3; Inhibitor of differentiation; Prostate cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2B; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION 3;

AGED; ARTICLE; CANCER GRADING; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM;

EID: 84879555404     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.19     Document Type: Article

References (46)

1. Yokota, Y., and S. Mori. 2002. Role of Id family proteins in growth control. J. Cell. Physiol. 190:21-28.
2. Wong, Y. C., X. Wang, and M. T. Ling. 2004. Id-1 expression and cell survival. Apoptosis 9:279-289.
3. Ruzinova, M. B., and R. Benezra. 2003. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 13:410-418.
4. Perk, J., A. Iavarone, and R. Benezra. 2005. Id family of helix-loop-helix proteins in cancer. Nat. Rev. Cancer 5:603-614.
5. Hasskarl, J., and K. Munger. 2002. Id proteins - tumor markers or oncogenes? Cancer Biol. Ther. 1:91-96.
6. Schoppmann, S. F., M. Schindl, G. Bayer, et al. 2003. Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int. J. Cancer 104:677-682.
7. Yang, H. Y., H. L. Liu, G. Y. Liu, et al. 2011. Expression and prognostic values of Id-1 and Id-3 in gastric adenocarcinoma. J. Surg. Res. 167:258-266.
8. Schindl, M., G. Oberhuber, A. Obermair, S. F. Schoppmann, B. Karner, and P. Birner. 2001. Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res. 61:5703-5706.
9. Forootan, S. S., Y. C. Wong, A. Dodson, et al. 2007. Increased Id-1 expression is significantly associated with poor survival of patients with prostate cancer. Hum. Pathol. 38:1321-1329.
10. Schindl, M., S. F. Schoppmann, T. Strobel, et al. 2003. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin. Cancer Res. 9:779-785.
11. Lyden, D., A. Z. Young, D. Zagzag, et al. 1999. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401:670-677.
12. Benezra, R., S. Rafii, and D. Lyden. 2001. The Id proteins and angiogenesis. Oncogene 20:8334-8341.
13. Carey, J. P., A. J. Asirvatham, O. Galm, T. A. Ghogomu, and J. Chaudhary. 2009. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer 9:173.
14. Ouyang, X. S., X. Wang, D. T. Lee, S. W. Tsao, and Y. C. Wong. 2002. Over expression of ID-1 in prostate cancer. J. Urol. 167:2598-2602.
15. Coppe, J. P., Y. Itahana, D. H. Moore, J. L. Bennington, and P. Y. Desprez. 2004. Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin. Cancer Res. 10:2044-2051.
16. Darby, S., S. S. Cross, N. J. Brown, F. C. Hamdy, and C. N. Robson. 2008. BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J. Pathol. 214:394-404.
17. Yu, X., X. Xu, B. Han, and R. Zhou. 2009. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation. Pathol. Oncol. Res. 15:91-96.
18. Ouyang, X. S., X. Wang, D. T. Lee, S. W. Tsao, and Y. C. Wong. 2001. Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble rat. Carcinogenesis 22:965-973.
19. Perk, J., I. Gil-Bazo, Y. Chin, et al. 2006. Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res. 66:10870-10877.
20. Gupta, G. P., J. Perk, S. Acharyya, et al. 2007. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc. Natl. Acad. Sci. USA 104:19506-19511.
21. Perry, S. S., Y. Zhao, L. Nie, S. W. Cochrane, Z. Huang, and X. H. Sun. 2007. Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance. Blood 110:2351-2360.
22. Li, J., T. Maruyama, P. Zhang, et al. 2010. Mutation of inhibitory helix-loop-helix protein Id3 causes gammadelta T-cell lymphoma in mice. Blood 116:5615-5621.
23. Asirvatham, A. J., M. A. Schmidt, and J. Chaudhary. 2006. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells. Prostate 66:921-935.
24. Asirvatham, A. J., J. P. Carey, and J. Chaudhary. 2007. ID1-, ID2-, and ID3-regulated gene expression in E2A positive or negative prostate cancer cells. Prostate 67:1411-1420.
25. Chaudhary, J., and M. Schmidt. 2006. The impact of genomic alterations on the transcriptome: a prostate cancer cell line case study. Chromosome Res. 14:567-586.
26. Schmidt, M., A. J. Asirvatham, and J. Chaudhary. 2010. Inhibitor of differentiation 1 (ID1) promotes cell survival and proliferation of prostate epithelial cells. Cell. Mol. Biol. Lett. 15:272-295.
27. Zhang, Z., D. G. Rosen, J. L. Yao, J. Huang, and J. Liu. 2006. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod. Pathol. 19:1339-1343.
28. Zhang, X., M. T. Ling, H. Feng, Y. C. Wong, S. W. Tsao, and X. Wang. 2004. Id-I stimulates cell proliferation through activation of EGFR in ovarian cancer cells. Br. J. Cancer 91:2042-2047.
29. Zielinski, A. J., S. Fong, J. Allison, et al. 2010. The helix-loop-helix Id-1 inhibits PSA expression in prostate cancer cells. Int. J. Cancer 126:2490-2496.
30. Yuen, H. F., Y. T. Chiu, K. K. Chan, et al. 2010. Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1. Br. J. Cancer 102:332-341.
31. Chetcuti, A., S. Margan, S. Mann, et al. 2001. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate 47:132-140.
32. Rogerson, L., S. Darby, T. Jabbar, et al. 2008. Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU Int. 102:364-370.
33. Ernst, T., M. Hergenhahn, M. Kenzelmann, et al. 2002. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am. J. Pathol. 160:2169-2180.
34. Lu, Y., Z. Cai, D. L. Galson, et al. 2006. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66:1311-1318.
35. Maw, M. K., J. Fujimoto, and T. Tamaya. 2009. Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers. BMC Cancer 9:430.
36. Si, C. F., J. Q. Guo, Y. M. Yang, et al. 2011. Nuclear and cytoplasmic Id-1 expression patterns play different roles in angiogenesis and lymphangiogenesis in gastric carcinoma. Ann. Diagn. Pathol. 15:46-51.
37. Zhang, X., M. T. Ling, Q. Wang, et al. 2007. Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J. Biol. Chem. 282:33284-33294.
38. Lingbeck, J. M., J. S. Trausch-Azar, A. Ciechanover, and A. L. Schwartz. 2005. E12 and E47 modulate cellular localization and proteasome-mediated degradation of MyoD and Id1. Oncogene 24:6376-6384.
39. Kamalian, L., S. S. Forootan, Z. Z. Bao, et al. 2010. Inhibition of tumourigenicity of small cell lung cancer cells by suppressing Id3 expression. Int. J. Oncol. 37:595-603.
40. Ciarrocchi, A., V. Jankovic, Y. Shaked, et al. 2007. Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS One 2:e1338.
41. Garrett-Engele, C. M., M. A. Tasch, H. C. Hwang, et al. 2007. A mechanism misregulating p27 in tumors discovered in a functional genomic screen. PLoS Genet. 3:e219.
42. Chassot, A. A., L. Turchi, T. Virolle, et al. 2007. Id3 is a novel regulator of p27kip1 mRNA in early G1 phase and is required for cell-cycle progression. Oncogene 26:5772-5783.
43. Roy, S., M. Gu, K. Ramasamy, et al. 2009. p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res. 69:1166-1173.
44. Roy, S., R. P. Singh, C. Agarwal, S. Siriwardana, R. Sclafani, and R. Agarwal. 2008. Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 7:1828-1835.
45. Chakravarti, A., M. DeSilvio, M. Zhang, et al. 2007. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J. Clin. Oncol. 25:3082-3089.
46. Mern, D. S., K. Hoppe-Seyler, F. Hoppe-Seyler, J. Hasskarl, and B. Burwinkel. 2010. Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells. Breast Cancer Res. Treat. 124:623-633.